NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study

[1]  S. Irvani,et al.  Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. , 2020, The Tohoku journal of experimental medicine.

[2]  X. T. Zhang,et al.  The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction , 2021, medRxiv.

[3]  M. Chung,et al.  Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19 , 2021, Vascular medicine.

[4]  Vivienne J. Zhu,et al.  Feasibility and utility of applications of the common data model to multiple, disparate observational health databases , 2015, J. Am. Medical Informatics Assoc..

[5]  Abin Thomas,et al.  Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study , 2020, Infectious Diseases and Therapy.

[6]  M. Fartoukh,et al.  Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. , 2011, Chest.

[7]  Ryan D. Chow,et al.  Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection , 2021, Journal of Virology.

[8]  J. Hewitt,et al.  Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19 , 2020, Journal of clinical medicine.

[9]  Zhongheng Zhang,et al.  Propensity score method: a non-parametric technique to reduce model dependence. , 2017, Annals of translational medicine.

[10]  M. Day.  Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists , 2020, BMJ.

[11]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[12]  I. Torjesen.  Ibuprofen can mask symptoms of infection and might worsen outcomes, says European drugs agency , 2020, BMJ.

[13]  Ju-Hyun Kim,et al.  Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study , 2020, Neurological Sciences.

[14]  G. Stein,et al.  Characterizing Long COVID: Deep Phenotype of a Complex Condition , 2021, EBioMedicine.

[15]  K. Bhaskaran,et al.  Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts , 2021, Annals of the Rheumatic Diseases.

[16]  N. Bhala,et al.  Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 , 2020, Arthritis & rheumatology.

[17]  N. Graham,et al.  ADVERSE EFFECTS OF ASPIRIN. ACETAMINOPHEN, AND IBUPROFEN ON IMMUNE FUNCTION, VIRAL SHEDDING, AND CLINICAL STATUS ON RHINOVIRUS‐INFECTED VOLUNTEERS , 1990, The Journal of infectious diseases.

[18]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[19]  A. Pottegård,et al.  Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study , 2020, PLoS medicine.

[20]  Hans-Ulrich Prokosch,et al.  Patient Cohort Identification on Time Series Data Using the OMOP Common Data Model , 2021, Applied Clinical Informatics.

[21]  Andrew E. Williams,et al.  Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative , 2021, JAMA network open.

[22]  Amber Dance.  What is a cytokine storm? , 2020 .

[23]  J. Micallef,et al.  Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection , 2020, Therapies.

[24]  Luis Unigarro,et al.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review , 2020, Diagnostic Microbiology and Infectious Disease.

[25]  Philip R. O. Payne,et al.  The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment , 2020, J. Am. Medical Informatics Assoc..

[26]  L. Køber,et al.  Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort Study , 2020, Clinical and translational science.

[27]  H. Sørensen,et al.  Association of Nonsteroidal Anti-inflammatory Drug Use and Adverse Outcomes Among Patients Hospitalized With Influenza , 2020, JAMA network open.

[28]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[29]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[30]  Publisher's Note , 2018, Anaesthesia.

[31]  D. Topham,et al.  Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. , 2009, Cellular immunology.

[32]  Yu-Chuan Li,et al.  Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers , 2015, MedInfo.

[33]  I. Youngster,et al.  Ibuprofen use and clinical outcomes in COVID-19 patients , 2020, Clinical Microbiology and Infection.

[34]  S. Jeong,et al.  Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea , 2020, Journal of clinical medicine.

[35]  Daniel O'Connor,et al.  Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID‐19 patients in Michigan, United States , 2020, Journal of internal medicine.

[36]  N. Moore,et al.  NSAIDs and COVID-19: A Systematic Review and Meta-analysis , 2021, Drug Safety.

[37]  J. Mitchell,et al.  The COVID‐19 ibuprofen controversy: A systematic review of NSAIDs in adult acute lower respiratory tract infections , 2020, British journal of clinical pharmacology.

[38]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.